Association of matrix metalloproteinase-1 (-1607 1G/2G) polymorphism with increased risk for oral squamous cell carcinoma

Anticancer Research

Volumn 27, Issue 1 A, 2007, Pages 459-464

  Vairaktaris, Eleftherios ^a   Yapijakis, Christos ^a,c   Derka, Spyridoula ^a   Serefoglou, Zoe ^a   Vassiliou, Stavros ^a   Nkenke, Emeka ^b   Ragos, Vassilis ^a   Vylliotis, Antonis ^a   Spyridonidou, Sofia ^a   Tsigris, Christos ^a   Yannopoulos, Athanasios ^a   Tesseromatis, Christina ^a   Neukam, Friedrich W ^b   Patsouris, Efstratios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Angiogenesis; Matrix metalloproteinase 1; MMP 1; Oncogenesis; Oral cancer; Polymorphism; Thrombophilia

Indexed keywords

INTERSTITIAL COLLAGENASE;

ADULT; AGED; ALCOHOL ABUSE; ANGIOGENESIS; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TOBACCO DEPENDENCE;

ADULT; AGED; ALLELES; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; MOUTH NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 33847676501     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Williams HK: Molecular pathogenesis of oral squamous carcinoma. J Clin Pathol 53: 165-172, 2000.
2. Song C, Xing D, Tan W, Wei Q and Lin D: Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res 61: 3272-3275, 2001.
3. Vairaktaris E, Yapijakis C, Wiltfang J, Ries J, Vylliotis A, Vassiliou S and Neukman FW: Are factor V and prothrombin mutations associated with increased risk of oral cancer? Anticancer Res 25: 2561-2566, 2005.
4. Vairaktaris E, Yapijakis C, Vylliotis A Wiltfang J, Kessler P, Ries J, Vassiliou S, Derka S and Neukman FW: Methylene-tetrahydrofolate reductase polymorphism and minor increase of risk for oral cancer. J Cancer Res Clin Oncol 132: 219-222, 2006.
5. Vairaktaris E, Yapijakis C, Serefoglou Z, Vylliotis A, Ries J, Nkenke E, Wiltfang J, Derka S, Vassiliou S, Springer I, Kessler P and Neukman FW: Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer. Oral Oncol 42(9): 888-892, 2006.
6. Vairaktaris E, Yapijakis C, Derka S, Derka S, Vassiliou S, Serefoglou Z, Vylliotis A, Wiltfang J, Springer I, Nkenke E, Kessler P and Neukam FW: Association of platelet Ia polymorphism with minor increase of risk for oral cancer. Eur J Surg Oncol 32: 455-457, 2006.
7. Ala-aho R and Kahari VM: Collagenases in cancer. Biochimie 87(3-4): 273-286, 2005.
8. Thomas GT, Lewis MP and Speight PM: Matrix metalloproteinases and oral cancer. Oral Oncol 35(3): 227-233, 1999.
9. Sang QX: Complex role of matrix metalloproteinases in angiogenesis. Cell Res 8(3): 171-177, 1998.
10. Bachmeier BE, Rohrbach H, De Waal J, Jochum M and Nerlich AG: Enhanced expression and activation of major matrix metalloproteinases in distinct topographic areas of invasive breast carcinomas. Int J Oncol 26(5): 1203-1207, 2005.
11. Wyatt CA, Geoghegan JC and Brinckerhoff CE: Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 cells: effects on matrix destruction and tumor growth. Cancer Res 65: 11101-11108, 2005.
12. Werb Z: ECM and cell surface proteolysis: regulating cellular ecology. Cell 91: 439-442, 1997.
13. Nagase H and Woessner JF: Matrix metalloproteinases. J Biol Chem 274(31): 21491-21494, 1999.
14. Johansson N, Ahonen M and Kahari VM: Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 57(1): 5-15, 2000.
15. Pardo A and Selman M: MMP-1: the elder of the family. Int J Biochem Cell Biol 37(2): 283-288, 2005.
16. Stetler-Stevenson WG, Aznavoorian S and Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9: 541-573, 1993.
17. Chambers AF and Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89(17): 1260-1270, 1997.
18. Murray GI, Duncan ME, O'Neil P, Melvin WT and Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 2(4): 461-462, 1996.
19. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT and Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 185(3): 256-261, 1998.
20. Gray ST, Wilkinks RJ and Yun K: Interstitial collagenase gene expression in oral squamous cell carcinoma. Am J Pathol 141(2): 301-306, 1992.
21. Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S and Harabuchi Y: Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 10: 634-640, 2004.
22. Aznavoorian S, Moore BA, Lister LD, Hallit SL, Windsor LJ and Engler JA: Membrane type I-matrix metalloproteinase-mediated degradation of type I collagen by oral squamous cell carcinoma cells. Cancer Research 61: 6264-6275, 2001.
23. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ and Brinckerhoff CE: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 58(23): 5321-5325, 1998.
24. Kanamori Y, Matsushima M, Minaguchi T, Kobayashi K, Sagae S, Kudo R, Terakawa N and Nakamura Y: Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and insertion/deletion polymorphism in its promoter region Cancer Res 59: 4225-4227, 1999.
25. Przybylowska K, Zielinska J, Zadrozny M, Krawczyk T, Kulig A, Wozniak P, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J and Blasiak J: An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymphnode metastasis in breast cancer. J Exp Clin Cancer Res 23: 121-125, 2004.
26. Zhu Yong, Spitz MR, Lei L, Mills GB and Wu X: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 61(21): 7825-7829, 2001.
27. Ghilardi G, Biondi ML, Mangoni J, Leviti S, DeMonti M, Guagnellini E and Scorza R: Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Caner Res 7: 2344-2346, 2001.
28. Ju W, Kang S, Kim JW, Park NH, Song YS, Kang SB and Lee HP: Promoter polymorphism in the matrix metalloproteinase-1 and risk of cervical cancer in Korean women. Cancer Lett 217(2): 191-196, 2005.
29. Ye S, Dhillon S, Turner SJ, Bateman AC, Theaker JM, Pickering RM and Day I: Invasiveness of cutaneous melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. Cancer Res 61: 1296-1298, 2001.
30. Jin X, Kuang G, Wei LZ, Li Y, Wang R, Guo W, Wang N, Fang SM, Wen DG, Chen ZF and Zhang JH: No association of the matrix metalloproteinase 1 promoter polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in northern China. World J Gastroenterol 11: 2385-2389, 2005.
31. Cao ZG and Li CZ: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances oral squamous cell carcinoma susceptibility in a Chinese population. Oral Oncology 42: 32-38, 2006.
32. Zinzidohoue F, Blons H, Hans S, Loriot MA, Houllier AM, Brasnu D, Laccourreye O, Tregouet DA, Stucker I and Laurent-Puig P: Single nucloetide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma. Anticancer Res 24: 2021-2026, 2004.
33. Borden P and Helter RA: Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryotic Gene Express 7(1-2): 159-178, 1997.
34. Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K and Okada Y: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or asteoarthritis. Ann Rheum Dis 59(6): 455-461, 2000.
35. Galis ZS, Sukhova GK, Lark M and Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94(6): 2493-2503, 1994.
36. Czekay RP and Loskutoff DJ: Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med 229: 1090-1096, 2004.
37. Coussens LM, Fingleton B and Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295(5564): 2387-2392, 2002.